Elicio Therapeutics, Inc. (NASDAQ:ELTX) Financings
Financings
| Raise | Date |
|---|---|
| Registered direct offering of shares of common stock Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1 Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc. Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline | Aug 13, 2026 |
| Registered direct offering of common stock Announced: about US$15M · Titan Partners, a division of American Capital Partners +1 Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc. Use of proceeds: Fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, the pipeline and platform, working capital and general corporate purposes | Jul 2, 2026 |
| At-the-market programme of shares under at-the-market program Tranche closed: US$11.1M raised | Nov 13, 2025 |
| Senior secured promissory note with warrants Closed: US$10M raised · Warrants at US$7.75 for 60 months Buyers: GKCC, LLC (existing investor; $10 million senior secured promissory note and warrants to purchase 103,225 shares) Use of proceeds: With existing cash, to support operations into Q1 2026, beyond the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025 | Jun 4, 2025 |